REFERENCES

  1. Komatsu K, Yamaguchi S, Utsumi D, Yamamoto I, Takahashi K. A Case of Dominant Dystrophic Epidermolysis Bullosa with a G2043R Mutation in the Type VII Collagen Gene. Acta Dermatovenerol Croat. 2020 Dec;28(4):251-252.
  2. Wang Z, Lin Y, Duan XW, Hang HY, Zhang X, Li LL. Misdiagnosed dystrophic epidermolysis bullosa pruriginosa: A case report. World J Clin Cases. 2021 May 6;9(13):3090-3094. doi: 10.12998/wjcc.v9.i13.3090.
  3. Ferreira S, Azevedo A, Velho GC, Sanches M, Selores M. Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. Australas J Dermatol. 2020 Nov;61(4):355-357. doi: 10.1111/ajd.13342. Epub 2020 Jun 10.
  4. Caroppo F, Milan E, Giulioni E, Belloni Fortina A. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol. 2022 May;36(5):e365-e367. doi: 10.1111/jdv.17887. Epub 2021 Dec 29.
  5. Jiang X, Wang H, Lee M, Lin Z. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib. JAMA Dermatol. 2021 Oct 1;157(10):1243-1244. doi: 10.1001/jamadermatol.2021.3174.
  6. Kwon IJ, Kim SE, Kim SC, Lee SE. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series. 2023 Dec 20. doi: 10.1111/1346-8138.17079. Epub ahead of print.